Evaluation of the immune response to chadox1 ncov-19 vaccine
- Post by: admin
- July 21, 2021
- Comments off
Evaluation of the immune response to chadox1 ncov-19 vaccine, in a cohort of participants in Colombo
Researchers:
Dr. T. M. R. R. Jinasena – Colombo South Teaching Hospital, Kalubowila
Dr. S. A. Gunawardena – National Hospital of Sri Lanka, Colombo 10
Dr. Saman Peduruhewa – Colombo South Teaching Hospital, Kalubowila
Introduction:
In 2019, a novel Corona virus, known as Severe Acute Respiratory Syndrome coronavirus-2 (SARS COV-2) was identified in Wuhan, China. It was declared as a pandemic by World Health Organization in March 2020. As of the February 2021, more than 113 million cases and more than 2.5 million deaths have been reported worldwide.
Ministry of Health, Sri Lanka has initiated the vaccination program for the high-risk category since the beginning of the year 2021 with COVISHIELD vaccine (ChAdOx1 nCOV-19 recombinant non–replicating viral vector vaccine). It induces a humoral response and showed a similar immune response as appeared in the convalescent plasma of infected individuals. Antibody response to any infection or vaccine could have differences due to genetic factors, comorbidities, age, sex ect. Therefore, the expected immune response has not observed in certain individuals after vaccination. The duration of the antibody existence varies between individuals but in average they last for 6 months in many.
Since the ChAdOx1 nCOV-19 is still in phase IV clinical trial stage, investigating the antibody response in Sri Lankan population will provide evidence for future public health guidelines and practice.
Objectives:
• To determine the general antibody response to the 1st dose of ChAdOx1 nCov-19 vaccine
